SOLV:NYSESolventum Corporation Analysis

Solventum (SOLV) is trading at $79.22, comfortably above its 20‑day ($77.39), 50‑day ($72.06) and 200‑day ($74.28) moving averages, with a bullish MACD crossover and a modestly positive RSI of 57.8, indicating upward momentum without being overbought. Volume is increasing and the price sits midway between a support level near $72.74 and resistance around $83.42, suggesting room for further upside while the technical backdrop remains supportive.
Fundamentally, the stock appears undervalued on a price‑to‑earnings basis (PE ≈ 9.7 versus an industry average of ~24.9) and delivers an impressive ROE of 34.8%, albeit fueled by a high debt‑to‑equity ratio of 106%. Recent Q1 results showed a 3% revenue dip but a sharp earnings contraction, yet the company beat adjusted expectations, reaffirmed its 2026 guidance, and is pursuing cost‑saving and portfolio‑optimization initiatives. Analyst sentiment is positive, with a consensus buy rating, mean target near $82‑85 and upside potential ranging from ~11% to 26%, while the DCF model indicates only modest upside (~3.7%).